The Irish health system has been struggling with the consequences of the use of the anti-drugs drugs rotenone and nalmefene.
This week the Irish Department of Health announced that it was withdrawing some anti-DPA products from the market as a result of concerns about their safety.
This decision follows a consultation, which has resulted in a review of the evidence base around these products.
These drugs are prescribed for treating conditions such as multiple sclerosis, fibromyalgia and asthma.
They are also prescribed to treat the symptoms of some conditions such a rheumatoid arthritis or chronic fatigue syndrome.
The decision has been welcomed by a number of organisations.
In a statement, the DPH said the withdrawal of the rotenones and nammefenes had “been driven by the concerns of the public and health professionals who have raised concerns about the safety of these drugs”.
It said this had led to the review of its drug policies and guidelines.
A number of other organisations also expressed concerns about these products in recent weeks, including the Irish Association of Pharmaceutical Professionals, the International Society for Drug Therapy (ISDT), the Irish Medical Association and the International Drug Policy Alliance.
This article was amended on 16 February 2018.